Categories: world

A new peanut allergy-using drug can mean a “sea change” in the treatment of food allergies, but it's not a cure. News

A major study provides the strongest evidence that children and adolescents can be desensitized to peanut allergies through controlled escalating…

A major study provides the strongest evidence that children and adolescents can be desensitized to peanut allergies through controlled escalating exposure to a substance that could otherwise trigger a life-threatening reaction – an advance that specialists said would probably mean the development of new food allergy drugs.

After a year of treatment with an experimental drug made by Aimmune Therapeutics, 67 percent of children and teens with peanut allergies could safely take in the equivalent of at least two peanuts compared with only 4 percent of those on placebo, according to the study published in the New England Journal of Medicine. However, that improvement was at a cost &#821

1; almost all participants in the study receiving the drug, a pharmaceutical preparation of peanut flour, suffered from side effects of some type and one in 10 withdraw from the trial due to gastrointestinal, skin or respiratory problems or systemic allergic reactions.

For several years, less studies have shown that exposure to escalating amounts of peanut allergy can desensitize humans against the potentially life-threatening effects of exposure, which may include anaphylactic shock but several external experts said that a large systematic study of 550 people could lead to the first treatment as approved by the Food and Drug Administration. The majority of participants were between 4 and 17 years old, the group where researchers found that the drug was effective.

“I think we are looking at going from nowhere where there is no approved treatment of food allergy, that a landscape where we probably will in some years have some options to offer our patients,” said Corinne Keet, a pediatrician at Johns Hopkins School of Medicine, which is not involved in the study, saying that it would be a “marine change” given the inadequate options today. “In the short term, the products coming to the market can not be cured, but I think there are a number of different approaches being investigated – and overall, the goal is more a cure.”

Aimmune, who financed the study, plans to file an application for the drug to the federal regulatory authorities next month and expects it to be launched late in 2019. It is unclear how much it would cost, how long patients would need to take it and about it would be covered by insurance.

“Currently, the advice will be ongoing treatment,” said Wayne Shreffler, director of the Food Allergy Center at the Massachusetts General Hospital and one of the authors who have received costs and fees from Aimmune. “Further studies will be needed to deal with a few years after a few years can change regular dosage. The vast majority of study participants tolerated treatment, and I expect the same to be true for its use in the” real world “When and if it’s approved.”

The treatment is not cure, and the treatment should not appeal to anyone with food allergies. Patients came to a clinic every two weeks for their dose to increase gradually under surveillance over a period of six months. They also took the drug at home every day.

“I think it’s important to remember what the goal of this treatment is – the goal is not to allow people to eat peanuts free,” says Daniel Adelman, Aimmune. “Children walk out the door every morning and their parents worry, it’s the day they will face peanuts and possibly have a life-threatening reaction. The goal of this treatment is to protect people against the potentially life-threatening reactions.”

Aimmune will expand the approach to other food allergies and test if a similar drug could work to desensitize children to egg allergies next year. [19659002] Experts warned that this type of treatment should not be started at home.

There are an estimated 6 million children with food allergies in the United States. In an accompanying editorial, Michael Perkin, from the public health research institute at St George’s University of London, pointed out that the potential market for a therapy is billions of dollars. The Aimmune drug was a degreased groundnut flour made by the hard manufacturing processes required by drugs, which Adelman stressed meant that it was free from variability that could carry the risk of delivering the wrong dose.

Keet said that anxiety is whether parents and children would understand the limits of the drug.

“We would still like to ask the patient to check labels and not take anything in the soil,” Keet said. “We do not know what people would stop doing with this partial protection – it can give people a false sense of security.” The function (f, b, e, v, n, t, s) {if (f.fbq) return, n = f.fbq = function () {n.callMethod?
n.callMethod.apply (n, argument): n.queue.push (argument)} if (! f._fbq) f._fbq = n;
n.push = n; n.loaded = 0 ;! n.version = & # 39; 2.0 & # 39 ;; n.queue = []; t = b.createElement (e); t.async = 0 !;
t.src = v; s = b.getElementsByTagName (e) [0]; s.parentNode.insertBefore (t, s)} (windows,
document, & # 39; script & # 39 ;, & # 39; https: //');
fbq (& # 39; init & # 39 ;, 1793977220844987 & # 39;);
fbq (& # 39; track & # 39 ;, PageView & # 39;);

Source link

Published by